Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IMATINIB Cause Multiple organ dysfunction syndrome? 119 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 119 reports of Multiple organ dysfunction syndrome have been filed in association with IMATINIB (Imatinib). This represents 0.3% of all adverse event reports for IMATINIB.

119
Reports of Multiple organ dysfunction syndrome with IMATINIB
0.3%
of all IMATINIB reports
97
Deaths
60
Hospitalizations

How Dangerous Is Multiple organ dysfunction syndrome From IMATINIB?

Of the 119 reports, 97 (81.5%) resulted in death, 60 (50.4%) required hospitalization, and 16 (13.4%) were considered life-threatening.

Is Multiple organ dysfunction syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IMATINIB. However, 119 reports have been filed with the FAERS database.

What Other Side Effects Does IMATINIB Cause?

Death (9,708) Drug ineffective (2,628) Nausea (2,379) Diarrhoea (2,203) Fatigue (1,810) Malignant neoplasm progression (1,716) Vomiting (1,599) Malaise (1,361) Drug intolerance (1,354) Drug resistance (1,293)

What Other Drugs Cause Multiple organ dysfunction syndrome?

TACROLIMUS (1,847) CYCLOPHOSPHAMIDE (1,597) MYCOPHENOLATE MOFETIL (1,566) PREDNISONE (1,525) DEXAMETHASONE (1,355) METHOTREXATE (1,317) METHYLPREDNISOLONE (1,278) RITUXIMAB (1,188) PREDNISOLONE (1,154) CYCLOSPORINE (933)

Which IMATINIB Alternatives Have Lower Multiple organ dysfunction syndrome Risk?

IMATINIB vs IMBRUVICA IMATINIB vs IMDEVIMAB IMATINIB vs IMEGLIMIN IMATINIB vs IMETELSTAT IMATINIB vs IMIDAPRIL

Related Pages

IMATINIB Full Profile All Multiple organ dysfunction syndrome Reports All Drugs Causing Multiple organ dysfunction syndrome IMATINIB Demographics